The laboratories of Dr. Alison Taylor and Dr. Fatemeh Momen-Heravi at Columbia University Herbert Irving Comprehensive Cancer Center (HICCC) are seeking an enthusiastic and exceptionally motivated postdoctoral research scientist for a joint project between the Taylor and Momen-Heravi laboratories on cancer genomics and transcriptomics. Applicants will be mentored by Dr. Alison Taylor and Dr. Fatemeh Momen-Heravi.
In this project, we will study the biologic determinants of cancer disparities through the lens of genomic and transcriptomic changes. Successful candidates will have a strong interest in the analysis of large-scale genetic datasets with the ultimate goal of discovering novel cancer drivers. The position will involve developing methods and pipelines for analysis of whole genome sequencing, transcriptome sequencing, chromosomal alterations (aneuploidy), and DNA copy number analysis. Prior experience with one or more of these data types is required.
Candidates should hold a PhD in computer science, bioinformatics, engineering, or a related field, and have experience in computational biology. In addition to technical and scientific knowledge, this individual should have excellent organizational and interpersonal skills, the ability to perform meticulous record keeping, and thrive in a collaborative and multi- disciplinary research setting.
The successful candidate will be highly motivated and collaborative with strong communication skills, and should have the desire to interface both with other computational/quantitative biologists and functional biologists. Applicants should have proficiency and substantial programming experience in R and/or Python.
Specific duties will include:
• Deployment of existing programs and algorithms for analysis of next-generation sequencing data in support of multiple projects.
• Development and maintenance of pipelines for analysis of next-generation sequencing data
• Maintenance/stewardship of large-scale datasets generated by the laboratory.
• Genomic/transcriptomic discovery of novel somatic alterations that drive cancer and the potential for developing independent projects in this area.